J Cancer 2018; 9(2):407-414. doi:10.7150/jca.21394

Review

Role of miR-483 in digestive tract cancers: from basic research to clinical value

Wei Zhou1*, Wanli Yang1*, Jiaojiao Ma1, Hongwei Zhang1, Zeng Li1, Lei Zhang2, Jinqiang Liu3, Zhenyu Han1, Hu Wang1, Liu Hong1✉

1. Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China;
2. Department of General Surgery, NO.406 Hospital, Dalian 116041, Liaoning Province, China;
3. Xinyang Cadres Sanatorium of Wuhan Military Logistics Base, Xinyang 464000, Henan Province, China.
*Co-first authors: These authors contributed equally to this work and should be considered co-first authors.

Abstract

Digestive tract cancers (DTCs) is the most common malignant tumors in the world. Despite surgery and medical technology have witnessed the increasing development and sharp advancement in the past decade, DTCs remain a critical concern with high morbidity and mortality. Since a class of small noncoding RNAs termed miRNAs were identified several years ago, increasing studies have attempted to illustrate the relationship between the specific miRNAs dysregulated expression levels and the diseases phenotypic changes. For example, microRNA-483 (miR-483) aberrant expression plays a pivotal part in tumor biology in a variety of human cancer, including DTCs. In this review, we focus on the present key findings from recent profiling studies, discuss the use of miR-483 as a novel biomarker for DTCs. At the same time, we emphasize the significant diversities and technical difficulties must be overcome before clinically relevant signatures arose. It is believed that this might provide researchers an insight into the molecular targeting cancer treatment.

Keywords: MicroRNA, miR-483, digestive tract cancers, regulatory mechanism, clinical value

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zhou W, Yang W, Ma J, Zhang H, Li Z, Zhang L, Liu J, Han Z, Wang H, Hong L. Role of miR-483 in digestive tract cancers: from basic research to clinical value. J Cancer 2018; 9(2):407-414. doi:10.7150/jca.21394. Available from http://www.jcancer.org/v09p0407.htm